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multiFISH, 51
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European, 251 (L)
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Isolated, 830
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Positive/negative symptoms, 1388
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Schizophrenia, 1388, 1450 (L)
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Selective sampling, 200, 211
Seminal vesicles, 1200 (L)
Semiparametric models, 1179
Sensorineural deafness, 813













Somatic mutation, 1000 (SG)
Sperm-derived mtDNA, 953
Spina bifida, 1204 (L)
Spinal muscular atrophy, 9 (E), 40, 1102
Spinocerebellar ataxia type 6 (SCA6), 336
Splice-site selection, 259 (GR)
Splice defects, 571





Sudden unexpected infants death, 852
Suicide gene therapy, 785 (GT)
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Synaptic transmission, 449 (L)
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